ClinicalTrials.gg
CompletedNCT00141232AFORRDUpdated Feb 18, 2021

Evaluating Atorvastatin With Omega-3 Fatty Acids in Cardiovascular Risk Reduction in Patients With Type 2 Diabetes

A Phase 4 interventional study of Atorvastatin and Omega-3 fatty acids in Diabetes, Type 2, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 59 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-18.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
810
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 25 studies testing atorvastatin in Diabetes Mellitus, Type 2 — none open to participants now, 1 under way, none of them phase 3. Atorvastatin · Diabetes Mellitus, Type 2.

Enrollment
4th of 25
810 · median 100
Started
2004
the only one that year
Phase 4
13 of 25
none open now
Registered
4th of 25
by date
Lead sponsor
4 of 25
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 25 studies testing atorvastatin in Diabetes Mellitus, Type 2, this one is the 4th largest by enrollment, is the only one that started in 2004, is one of 13 in phase 4, and was the 4th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 25 studies testing atorvastatin in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About atorvastatin

Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 25 studies testing atorvastatin in Diabetes Mellitus, Type 2 as a file.
02

Study summary

The AFORRD trial is asking three important questions:

What proportion of people with Type 2 Diabetes are likely to be treated satisfactorily with a fixed dose of a statin that lowers blood cholesterol levels to help reduce the risk of heart disease? To what extent do omega-3 fatty acids lower blood triglyceride levels when given with or without a statin? Are there simple techniques that can help people to take their tablets on a regular basis?

03

Conditions studied

  • Diabetes, Type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • They have a diagnosis of Type 2 Diabetes Mellitus for at least 3 months prior to entry.
  • Are not known to have had a cardiovascular event

Exclusion criteria

Exclusion Criteria:

  • They are taking prescribed lipid lowering therapy
  • Have triglycerides > or = 8.0 mmol/L
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double
Enrollment
810 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Prim objective (16 wks) for atorvastatin: Proportion of pats. who achieve measured

  2. LDL levels <2.6 mmol/L (<100 mg/dl) Prim object (16 wks) for Omega-3 fatty acid:

  3. Prop of pats. who achieve measured triglycerides <1.5 mmol/L (<200 mg/dl)

Secondary outcomes

  1. Prop of pats who achieve LDL levels <2.6 mmol/L (<100 mg/dl) at 52 weeks, taking into account whether the patient received additional atorvastatin therapy or placebo at week 16.

  2. Prop of pats who achieve triglycerides <1.5 mmol/L (<200 mg/dl) at 52 weeks.

07

Study locations

59 sites
  • Pfizer Investigational Site
    Irvine, Ayrshire KA12 OAY, United Kingdom
  • Pfizer Investigational Site
    Farnworth, Bolton BL4 9AH, United Kingdom
  • Pfizer Investigational Site
    Thornhill, Cardiff CF14 9BB, United Kingdom
  • Pfizer Investigational Site
    Fowey, Cornwall PL23 1DT, United Kingdom
  • Pfizer Investigational Site
    Launceston, Cornwall PL15 9HH, United Kingdom
  • Pfizer Investigational Site
    Penzance, Cornwall TR18 4JH, United Kingdom
  • Pfizer Investigational Site
    Penzance, Cornwall TR19 7HX, United Kingdom
  • Pfizer Investigational Site
    Saltash, Cornwall PL12 6DL, United Kingdom
  • Pfizer Investigational Site
    St Austell, Cornwall PL26 7RL, United Kingdom
  • Pfizer Investigational Site
    Darlington, County Durham DL16 6QA, United Kingdom
  • Pfizer Investigational Site
    Newton Aycliffe, County Durham DL5 5NH, United Kingdom
  • Pfizer Investigational Site
    Three Bridges, Crawley RH10 1LL, United Kingdom
  • Pfizer Investigational Site
    Plymouth, Devon PL5 3JB, United Kingdom
  • Pfizer Investigational Site
    Plymouth, Devon PL6 7TH, United Kingdom
  • Pfizer Investigational Site
    Bexhill on Sea, East Sussex TN39 4SP, United Kingdom
  • Pfizer Investigational Site
    Bexhill-On-Sea, East Sussex TN40 2SD, United Kingdom
  • Pfizer Investigational Site
    Bath, England BA2 4JT, United Kingdom
  • Pfizer Investigational Site
    Dronfield, Sheffield, England S18 1RU, United Kingdom
  • Pfizer Investigational Site
    Surrey, England CR7 7JN, United Kingdom
  • Pfizer Investigational Site
    Halstead, Essex CO9 1EX, United Kingdom
  • Pfizer Investigational Site
    Stonehouse, Gloucestershire GL10 2NG, United Kingdom
  • Pfizer Investigational Site
    Southampton, Hampshire SO31 7DQ, United Kingdom
  • Pfizer Investigational Site
    Hildenborough, Kent TN11 9HL, United Kingdom
  • Pfizer Investigational Site
    Thorneton-Clevely, Lancashire FY5 3LF, United Kingdom
  • Pfizer Investigational Site
    Balham, London SW12 8EU, United Kingdom
  • Pfizer Investigational Site
    Fulham, London SW6 2HQ, United Kingdom
  • Pfizer Investigational Site
    Tooting, London SW17 9SJ, United Kingdom
  • Pfizer Investigational Site
    Hayes, Middlesex UB4 0SF, United Kingdom
  • Pfizer Investigational Site
    Wellingborough, Northamptonshire NN8 4RW, United Kingdom
  • Pfizer Investigational Site
    Cookstown, Northern Ireland BT80 8BN, United Kingdom
  • Pfizer Investigational Site
    Frome, Somerset BA11 1EZ, United Kingdom
  • Pfizer Investigational Site
    Fetcham, Surrey KT22 9LE, United Kingdom
  • Pfizer Investigational Site
    Woking, Surrey, United Kingdom
  • Pfizer Investigational Site
    Crawley, West Sussex RH10 7DX, United Kingdom
  • Pfizer Investigational Site
    Leeds, West Yorkshire LS12 1JE, United Kingdom
  • Pfizer Investigational Site
    Bradford-on-Avon, Wiltshire BA1 5DQ, United Kingdom
  • Pfizer Investigational Site
    Melksham, Wiltshire SN12 6UN, United Kingdom
  • Pfizer Investigational Site
    Swindon, Wiltshire SN25 4YZ, United Kingdom
  • Pfizer Investigational Site
    Trowbridge, Wiltshire BA14 7EG, United Kingdom
  • Pfizer Investigational Site
    Warminster, Wiltshire BA12 9AA, United Kingdom
  • Pfizer Investigational Site
    Sheffield, Yorkshire S7 2DW, United Kingdom
  • Pfizer Investigational Site
    Bath, BA2 1NH, United Kingdom
  • Pfizer Investigational Site
    Bath, BA2 3HT, United Kingdom
  • Pfizer Investigational Site
    Belfast, BT4 1NT, United Kingdom
  • Pfizer Investigational Site
    Birmingham, B37 7TR, United Kingdom
  • Pfizer Investigational Site
    Bucks, HP22 5LB, United Kingdom
  • Pfizer Investigational Site
    Chesterfield, S40 4TF, United Kingdom
  • Pfizer Investigational Site
    Chippenham, Wiltshire, SN15 2SB, United Kingdom
  • Pfizer Investigational Site
    Cornwall, TR18 2RE, United Kingdom
  • Pfizer Investigational Site
    County Antrim, Northern Ireland, BT41 3AE, United Kingdom
  • Pfizer Investigational Site
    Darlington, DL3 6HZ, United Kingdom
  • Pfizer Investigational Site
    Dundee, DD2 5NH, United Kingdom
  • Pfizer Investigational Site
    Dundee, DD4 6QY, United Kingdom
  • Pfizer Investigational Site
    East Sussex, TN40 3RJ, United Kingdom
  • Pfizer Investigational Site
    Isle Of Wight, PO32 6RR, United Kingdom
  • Pfizer Investigational Site
    Isle Of Wight, PO33 2PT, United Kingdom
  • Pfizer Investigational Site
    London, N19 5EW, United Kingdom
  • Pfizer Investigational Site
    London, SW19 6DA, United Kingdom
  • Pfizer Investigational Site
    Westbury, BA13 3JD, United Kingdom
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2004 and a completion of Jul 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2005
First posted
Sep 1, 2005
Start
Nov 2004
CompletionActual
Jul 2006
Last update
Feb 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00141232
Collaborators
Churchill Hospital
Responsible party
Sponsor
First posted
Sep 1, 2005
Start date
Nov 2004
Completion
Jul 2006
Last update
Feb 18, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Atorvastatin · Omega-3 fatty acid

Start the discussion